Abstract
Background
Patients with Immune Mediated Inflammatory Diseases (IMIDs) using immunosuppressive therapy are at increased risk of infections, including vaccine-preventable infections. In this study, we aimed to evaluate whether patients with IMIDs on systemic immunosuppressive therapy are vaccinated according to current guidelines.
Methods
A survey was sent out, between August 2022 and March 2023, to all patients with IMIDs that visited the departments of dermatology, rheumatology and gastroenterology at an academic and regional hospital in Rotterdam, the Netherlands. Patient-reported vaccination status was compared to the Dutch guidelines on vaccinations in patients with chronic inflammatory diseases.
Results
A total of 1,905/5,987 patients responded to the survey (response rate 32%). After exclusion of patients without systemic immunosuppressive medication, the study population comprised 1,390 patients, median age 56 years (IQR 42–66) and 41% male. Most patients (92%) had been vaccinated according to the Dutch National Immunization Program. Before starting immunosuppressive therapy, 2% of the patients who were still considered at risk according to the Dutch guideline were vaccinated for measles, and 4% for diphtheria/tetanus/polio (DT-IPV). Additionally, 62% of patients received an annual influenza vaccine, 16% received a five-yearly pneumococcal vaccine, and 91% were fully vaccinated against COVID-19.
Conclusion
Patients with IMIDs on immunosuppressive therapy are not vaccinated in accordance with the guidelines. Implementation strategies to improve the vaccination rates for patients with IMIDs should specifically focus on vaccinating against measles and diphtheria/tetanus/polio, and periodic vaccination against pneumococcal and influenza infections.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Chronic Immune Mediated Inflammatory Diseases (IMIDs) refer to a group of inflammatory diseases that can affect different organs, e.g. psoriasis, inflammatory bowel disease (IBD) and rheumatoid arthritis (RA). Patients with IMIDs are frequently treated with immunomodulators, small molecules or biologics. Immunosuppressive therapy is associated with an increased risk for severe infections [1].
Several infections may be prevented by vaccinating against these infections, including the highly prevalent infections with influenza virus and Streptococcus pneumoniae. A higher incidence of influenza infections has been reported in patients with RA compared to matched controls (409 vs. 306 cases per 100,000 patient-years), and a 2.8-fold increase in incidence of complications [2]. Similarly, the incidence risk rate of an influenza infection was 1.54 and a higher hospitalization rate (5.4% vs. 1.85%) was reported for patients with IBD compared to non-IBD [3]. For pneumococcal infections, the reported incidence of invasive pneumococcal disease (IPD) is higher in patients with chronic inflammatory diseases compared to healthy controls (65 vs. 10 per 100,000 persons) with a mortality rate ranging from 0 to 10% [4], and a 2.1–2.7 fold increased when using immunosuppressive therapy [5]. National and international guidelines on standard immunization schedules for patients with IMIDs are based on these risks. [6,7,8,9]
Significant barriers for vaccinating are seen for both patients and the treating physicians. The barriers for patients include limited awareness regarding recommended vaccinations, concerns about potential side effects and high costs due to insufficient funding and reimbursement [10,11,12,13]. Furthermore, treating physicians face challenges in providing patients with relevant information and prescription of vaccinations as a result of insufficient knowledge concerning immunization schedules, an abundance of guidelines, the insufficient reimbursement for patients and time constraints during outpatient consultations. Finally, vaccination care is hampered by the involvement of many different stakeholders, e.g. patients, healthcare providers in primary and secondary care, pharmaceutical companies and healthcare institutions, which often results in inadequate communication among healthcare providers regarding the responsibility for prescription and administration of vaccinations [11, 14].
The impact of above-mentioned barriers to vaccinate patients with IMIDs on vaccination rates is unknown. The aim of this study is to assess patient-reported vaccination status in patients with IMIDs on immunosuppressive treatment. The secondary aim is to explore how patients had been informed about the recommended vaccinations.
Methods
Study design
This observational, non-interventional study was performed at the Erasmus MC academic hospital (EMC) and the Franciscus Gasthuis & Vlietland regional teaching hospital (FGV) in Rotterdam, the Netherlands. Patients with a confirmed IMID diagnosis who were treated at the outpatient clinic between 2021 and 2023, were selected by a data team based on Diagnosis Treatment Combination codes (DTC). By means of a DTC performance code established by the Dutch Healthcare Authority (NZa), a DTC describes the closed and validated process of specialist medical care. The online questionnaire was sent out to patients of the EMC during the period of August to October 2022, and FGV during January to March 2023. Selected patients received the online questionnaire, after digital informed consent was provided. Patients received a reminder after 4 weeks by e-mail. The questionnaire was designed using a secure web-based system (Castor Electronic Data Capture). Medication information was obtained from medical records and included in the questionnaire. For analyses, only patients on systemic immunosuppressive medication were selected.
Patient population
Patients aged 18 years or older, with a confirmed IMID diagnosis and who received immunosuppressive therapy at the outpatient clinic were included. Specific IMID diagnoses were selected at the departments of (a) dermatology, i.e. atopic eczema, hidradenitis suppurativa (HS), psoriasis, pemphigoid/pemphigus, (b) gastroenterology, i.e. Crohn’s disease, ulcerative colitis, and (c) rheumatology, i.e. psoriatic arthritis, RA, spondyloarthropathy.
Questionnaire
Close-ended questions were asked regarding the baseline patient and disease characteristics. Vaccination status was evaluated for vaccinations within the Dutch National Immunization Program (NIP) (Supplementary Table 1), COVID-19 vaccination, travel vaccinations, vaccinations before the start of immunosuppressive therapy and additional vaccinations (Supplementary Table 2). Patients were also asked how they had been informed about current vaccination care, and if they were satisfied with the information they had received. If patients were dissatisfied, they were asked how information on vaccination care could be improved.
Guidelines
The patient reported vaccination status was compared to the Dutch guideline on vaccinations in patients with chronic inflammatory diseases [6]. A summary of the checklist of this guideline is depicted in Supplementary Table 3.
Data synthesis and statistical analysis
Responses to the closed-ended questions from the questionnaire were entered in a database for descriptive analyses with IBM SPSS Statistics for Windows, version 25 (IBM Corp., Armonk, N.Y., USA). Data is presented as count and percentage for categorical variables, and median and interquartile range (IQR) for non-normally distributed variables.
Results
Baseline characteristics
The survey was sent out to 5,987 patients with IMIDs, of whom 1,923 patients completed the questionnaire (response rate 32.1%). A total of 1,390 patients fulfilled the inclusion criteria (Fig. 1). Median age was 56 years (IQR 42–66), 40.9% was male, and 63.4% was treated at the EMC (academic hospital) vs. 36.6% at the FGV (regional hospital). Patients were treated by a dermatologist (n = 328, 23.6%), rheumatologist (n = 821, 59.1%) or gastroenterologist (n = 436, 31.4%), and 182 patients (13.1%) were treated for more than one diagnosis. Medication use included systemic corticosteroids (22%), immunomodulators (57.8%), JAK inhibitors (4.2%), and biologicals (62.2%) (Table 1).
Vaccination status according to the Dutch guideline
Of all patients, 92.4% (n = 1,285) had received the childhood vaccinations in accordance with the NIP, and 2.3% (n = 32) had received a subset of these vaccinations (Fig. 2A). Of the patients who were not fully vaccinated for diphtheria/tetanus/polio (DT-IPV), 3.9% (n/N = 12/305) had received the diphtheria/tetanus/wheezing cough/polio (DT(aP)-IPV) vaccination before the start of immunosuppressive therapy. 2.4% (n/N = 8/331) of the patients at risk of measles infection received the Mumps/Measles/Rubella (MMR) vaccination prior to immunosuppressive therapy, and 7.6% (n/N = 25/331) of those at risk received the vaccination prior to international travel. In addition, of all patients, 2.9% (n = 41) received a booster DT(aP)-IPV vaccination prior to immunosuppressive therapy, and 6.9% (n = 96) received a booster MMR vaccination prior to immunosuppressive therapy or for travelling abroad.
61.6% of all patients received the annual influenza vaccination, and 16.3% received the pneumococcal vaccination every five years. Influenza and pneumococcal vaccination rates were higher among elderly patients who surpassed the age limit for the national vaccination program (> 60 years for influenza and > 66 years for pneumococcal). Highest vaccination rates were observed in patients treated by a rheumatologist, and when treated in a regional hospital. Analyzing vaccination rates based on diagnosis showed that both the influenza and pneumococcal vaccination rates were highest in patients with RA (68.8%, and 25%, respectively). Lowest vaccination rates were observed in patients with HS for both the influenza vaccination (32.7%) and pneumococcal vaccination (0%) (Table 2).
Finally, 92.6% (n = 1,287) of all patients were fully vaccinated with the COVID-19 vaccination, with 81.7% having received at least one booster vaccination (Table 3). Among all patients, 597/1,390 patients received travel vaccinations (Fig. 2B). 122/1,390 patients received vaccinations prior to the start of immunosuppressive therapy (Fig. 2C). Additional vaccinations for other reasons (e.g. work-related, after a wound or catch-up childhood vaccinations) were reported by 182/1,390 patients (Fig. 2D).
Vaccination status in patients with IMIDs (n = 1,390). Note: the vaccination rates are described as a percentage of the total population (n = 1,390). The different panels describe the vaccination status according to patients self-report for (A) within the Dutch National Immunization Program, (B) Travel vaccinations, (C) Vaccinations prior to initiation of immunosuppressive therapy (D) additional vaccinationsa. * = fully vaccinated describes patients which received the childhood vaccinations based on birth year and implementation date. Partially vaccinated describes the patients who only received a subset of the childhood vaccinations. a = Other reasons includes e.g. work-related vaccinations, catch-up vaccinations for people who missed the routine children vaccinations according to the NIP, and after an abrasion or bite wound. Abbreviations: aP, Whooping cough; D, Diphtheria; HAV, Hepatitis A; HBV, Hepatitis B; Hib, Haemophilus influenzae type b; HPV, Human Papillomavirus; H1N1, Influenza (Mexican/Spanish flu); IPV, Polio; JE, Japanese encephalitis; Men, Meningococcal; MenC, Meningococcal type C; MMR, Mumps, Measles and Rubella; PCV, Pneumococcal; Pox, Smallpox; R, Rubella; T, Tetanus TBC, Tuberculosis; TBE, Tick-borne encephalitis; Ty, Typhoid fever; VZV, Varicella Zoster virus; YF, Yellow fever
Patient education
Regarding patient education about recommended vaccinations in general, 69.4% (n = 965) reported being satisfied with the received information. Of these patients, 61.9% (n = 597) received information from their medical team, 48.7% (n = 470) searched for information themselves, and 25.1% (n = 242) neither received nor searched for information. Figure 3 illustrates the different ways patients were informed about the required vaccinations before initiating immunosuppressive therapy. Of the patients who were dissatisfied with the information they received, most patients would prefer to receive information from their medical team (53.6%; n = 228), and specifically their treating physician (77.2%; n = 328) (Fig. 4).
28.6% (n = 398) of patients recalled having discussed the recommended vaccinations before the start of immunosuppressive therapy. No difference in advising vaccinations prior to immunosuppressive therapy was observed between the academic and regional teaching hospital or between different treating specialties.
Discussion
This observational study shows a high vaccination rate with regard to the vaccinations according to the NIP, COVID-19 vaccinations and travel vaccinations in patients with IMIDs on systemic immunosuppressive therapy, whereas the vaccination rates prior to initiating immunosuppressive therapy as well as influenza and pneumococcal vaccination were considerably lower. This study identifies specific components of the vaccination program that require implementation strategies to improve the vaccination rates for patients with IMIDs on immunosuppressive treatment who remain at risk for vaccine-preventable infections in the Dutch population. Most importantly, a focus is required on pneumococcal vaccination (unvaccinated population up to 84%), influenza (38%), measles (21%), and DT-IPV (21%).
The uptake of influenza vaccinations and pneumococcal vaccinations shows a high variation according to available literature. A recent systematic review and meta-analysis on interventions to increase vaccine uptake in patients with IBD and RA, shows that the range of uptake for influenza ranges from 4 to 82% and for pneumococcal from 0.3 to 80% [16]. Differences in vaccination rates between the studies are probably explained by the differences in the organization of the vaccination care, access to the vaccines, primary documentation, patient education, and patient and physicians attitude towards vaccinations. To improve vaccination uptake all these aspects require consideration.
Explanations for the high vaccination uptake (> 90%) for vaccinations included in the NIP and for the COVID-19 vaccination in our study include a nationally centralized program with one clear stakeholder, the Dutch Ministry of Health, Welfare and Sport (RIVM), and patient education. The NIP is offered to all children in the Netherlands and new parents automatically receive information about the vaccinations and an invitation for their children [17]. Moreover, during the COVID-19 pandemic, a national vaccination program was swiftly implemented and patients received an invite for the vaccination based on age and comorbidities. Extensive media coverage emphasizing the importance of COVID-19 vaccinations possibly contributed to the high vaccination uptake [18]. Learning from these programs, including centralized organization, funding and education may benefit specific programs in patients with IMIDs.
These important aspects probably also explain the higher vaccination rates among older IMID patients as compared to younger patients, since all individuals above a specific age limit (> 60 years for influenza and > 66 years for pneumococcal) are invited to the national program to receive an influenza or pneumococcal vaccination. This might partially explain differences observed in this study between the overall vaccination rates in patients with HS versus patients with RA. Implementation strategies for a vaccination program for younger patients are required since our study showed that only half of these patients received an annual influenza vaccination and only 5% received the five-yearly pneumococcal vaccination. This implementation program may also focus on the MMR and DT-IPV vaccination. Further evaluation of the indications for the newer recombinant herpes zoster vaccination for patients with IMIDs are required before implementation. Current data and guidelines are equivocal on this indication and recommend to consider this vaccination on individual basis [6].
The findings highlight key factors influencing the implementation of vaccination guidelines. Adequate patient education, well-defined stakeholder collaborations, and comprehensive national vaccination programs contribute to high vaccination rates. However, when the responsibility lies within the medical team, vaccination rates are considerably lower. Current education is insufficient and recommended vaccinations prior to immunosuppressive therapy are often not discussed by health care providers. In this study we observed considerable differences between vaccination rates in specific departments, such as a higher vaccination rate in patients with RA. These variations probably result from differences in the logistical implementation and execution of vaccination care across departments and hospitals. For instance, the higher vaccination rate observed among patients with RA could potentially be due to comprehensive patients education facilitated by specialized nurses. Overall, patients with IMIDs have some general knowledge about vaccinations (e.g. efficacy, costs, protection for severe diseases), but understanding specific details like vaccine efficacy and contraindications with immunosuppressive therapy is limited, varying with education levels [19]. This underlines the need for thorough patient education to improve vaccination care for patients with IMIDs. Studies show that effective education improves vaccination uptake by raising awareness among both patients and health care providers [20,21,22,23]. Sustained education efforts are crucial for long-term vaccination uptake, addressing vaccine hesitancy, and considering early education after diagnosis, preferably before immunosuppressive treatment is contemplated. Our study underscores the vital role of the medical team, particularly treating physicians, in providing this information to patients regarding vaccinations.
Patients and physicians attitude towards vaccinating are not taken into account in this study, which might contribute to a lower vaccination uptake. Surprisingly, a quarter of the patients who were satisfied with the information about the recommended vaccinations did not receive any information at all, which might indicate a group of patients with a contentedly ignorant attitude. From the physicians point of view, the recommendations may vary among specialists because of differing assessments of the necessity for these vaccinations, possibly due to the perceived relatively low prevalence of severe infections. Further research is needed to assess the acceptance of the guidelines by treating physicians.
A few limitations of this study need to be taken into account. First, it is important to note that this study is based on self-reported vaccination status by patients. This may have led to a potential recall bias. Unfortunately, the absence of a national registration system for vaccinations leaves limited options for evaluating vaccination status and poses a challenge for healthcare providers in accurately determining the vaccination status of their patients. Secondly, the travel and additional vaccinations may introduce potential bias, as it involves only patients who were conscious of the necessity for vaccinations. The exclusion of patients who were unaware of recommended vaccinations may result in an overestimation of the overall vaccination rate. Finally, it is important to note that this study was conducted in the Netherlands, which limits the generalizability of the findings to in other countries. The variation in vaccination programs and care across different countries need to be taken into account.
Conclusion
Patients with Immune Mediated Inflammatory Diseases on immunosuppressive therapy are not vaccinated in accordance with the current guidelines. Patients are thus insufficiently protected against vaccine-preventable infections, including influenza and pneumococcal infections. Important facilitators include patient education, well-defined stakeholder collaborations and comprehensive national vaccination programs. Barriers persist within the medical team, highlighting the need for better implementation strategies of current vaccination guidelines and effective education for patients and physicians.
Data availability
Data are available on reasonable request.
References
Kirchgesner J, Lemaitre M, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Risk of Serious and opportunistic infections Associated with Treatment of Inflammatory Bowel diseases. Gastroenterology. 2018;155(2):337–46. e10.
Blumentals WA, Arreglado A, Napalkov P, Toovey S. Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study. BMC Musculoskelet Disord. 2012;13:158.
Tinsley A, Navabi S, Williams ED, Liu G, Kong L, Coates MD, Clarke K. Increased risk of Influenza and Influenza-Related complications among 140,480 patients with inflammatory bowel disease. Inflamm Bowel Dis. 2019;25(2):369–76.
van Aalst M, Lötsch F, Spijker R, van der Meer JTM, Langendam MW, Goorhuis A, et al. Incidence of invasive pneumococcal disease in immunocompromised patients: a systematic review and meta-analysis. Travel Med Infect Dis. 2018;24:89–100.
Shigayeva A, Rudnick W, Green K, Chen DK, Demczuk W, Gold WL, et al. Invasive pneumococcal Disease among Immunocompromised persons: implications for Vaccination Programs. Clin Infect Dis. 2016;62(2):139–47.
Vaccinatie bij chronisch inflammatoire aandoeningen. Dutch Ministry of Health, Welfare and Sport; [ https://lci.rivm.nl/richtlijnen/vaccinatie-bij-chronisch-inflammatoire-aandoeningen#2-checklists-bij-vaccinatiezorg
Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39–52.
Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8(6):443–68.
Wine-Lee L, Keller SC, Wilck MB, Gluckman SJ, Van Voorhees AS. From the Medical Board of the National Psoriasis Foundation: vaccination in adult patients on systemic therapy for psoriasis. J Am Acad Dermatol. 2013;69(6):1003–13.
Bridges MJ, Coady D, Kelly CA, Hamilton J, Heycock C. Factors influencing uptake of influenza vaccination in patients with rheumatoid arthritis. Ann Rheum Dis. 2003;62(7):685.
Colmegna I, Valerio V, Gosselin-Boucher V, Lacoste G, Labbe S, Lavoie KL, et al. Barriers and facilitators to influenza and pneumococcal vaccine hesitancy in rheumatoid arthritis: a qualitative study. Rheumatology (Oxford). 2021;60(11):5257–70.
Melmed GY, Ippoliti AF, Papadakis KA, Tran TT, Birt JL, Lee SK, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006;101(8):1834–40.
Loubet P, Verger P, Abitbol V, Peyrin-Biroulet L, Launay O. Pneumococcal and influenza vaccine uptake in adults with inflammatory bowel disease in France: results from a web-based study. Dig Liver Dis. 2018;50(6):563–7.
Adviesrapport. ‘Vaccinatiezorg voor medische risicogroepen: wie neemt de regie?’: Zorginstituut Nederland; 2021 [ https://www.zorginstituutnederland.nl/publicaties/adviezen/2021/06/11/advies-vaccinatiezorg-voor-medische-risicogroepen
(CBS) DCBoS. 2019 [ https://www.cbs.nl/nl-nl/nieuws/2019/33/verschil-levensverwachting-hoog-en-laagopgeleid-groeit/opleidingsniveau
Patel J, Noureldin M, Fakhouri D, Farraye FA, Kovar-Gough I, Warren B, et al. Interventions increase vaccination rates in inflammatory bowel disease and rheumatoid arthritis: a systematic review and Meta-analysis. Dig Dis Sci. 2023;68(7):2921–35.
Dutch National Immunisation Programme. Dutch Ministry of Health, Welfare and Sport; [ https://rijksvaccinatieprogramma.nl/english
Coronavirus vaccination campaign in the Netherlands. Government of the Netherlands; [ https://www.government.nl/topics/coronavirus-covid-19/dutch-vaccination-programme/covid-19-vaccination-campaign
Abreu C, Martins A, Branco E, Rocha R, Sarmento A, Magro F. Vaccines - beliefs and concerns: the voice of patients with inflammatory immunomediated diseases. Eur J Gastroenterol Hepatol. 2023;35(8):848–53.
Valerio V, Bazan MC, Wang M, Mazer BD, Pineau CA, Hazel EM, et al. A multimodal intervention increases influenza vaccine uptake in rheumatoid arthritis. Clin Rheumatol. 2021;40(2):575–9.
Webb NJ, Lindsley J, Stockbridge EL, Workman A, Reynolds CD, Miller TL, et al. Effectiveness of an intervention to overcome influenza vaccine hesitancy in specialty clinic patients. Med (Baltim). 2022;101(30):e29786.
Coenen S, Weyts E, Jorissen C, De Munter P, Noman M, Ballet V, et al. Effects of Education and Information on Vaccination Behavior in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(2):318–24.
Malhi G, Rumman A, Thanabalan R, Croitoru K, Silverberg MS, Hillary Steinhart A, Nguyen GC. Vaccination in inflammatory bowel disease patients: attitudes, knowledge, and uptake. J Crohns Colitis. 2015;9(6):439–44.
Acknowledgements
We would like to thank the patient organization, Crohn & Colitis NL, for their input in developing the questionnaire.
Funding
An education grant was received by Pfizer Inc.
Author information
Authors and Affiliations
Contributions
NP did conceptualization, data curation, formal analysis, investigation, methodology, validation, visualization and writing – original draft; CJW did writing – review & editing; MV did conceptualization and writing – review & editing; MBAvD did conceptualization and writing – review & editing; SLS did writing – review & editing; FC did writing – review & editing; RLW did writing – review & editing; ACV did conceptualization, funding acquisition, methodology, project administration, supervision and writing – review & editing.
Corresponding author
Ethics declarations
Ethics approval
This study was approved by the Institutional Review Board (IRB) of the EMC, MEC-2022-0196.
Competing interests
CJW received grants from ZonMW, Falk and Pfizer, has received consulting fees from Janssen, Galapagos, and Pfizer, has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Ferring and AbbVie and had leadership roles in the European Crohn’s & Colitis organisation, United European Gastroenterology council and the Dutch Association for Gastroenterology (NVGE); MV received research funding/advisory board fees from Novartis, UCB, Janssen, AbbVie, Lilly, and Pfizer; MBAvD reports grants and has served on the advisory board or as a speaker for Novartis and Janssen-Cilag. He has also has served on the advisory board or as a speaker for Abbvie, Leopharma, BMS, Celgene, Lilly, MSD, Pfizer, and Sanofi-Genzyme; RLW has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Ferring, Pfizer, Galapagos, AbbVie and Janssen; ACV has served on advisory boards for Takeda, Janssen, Bristol Myers Squibb, Abbvie, Pfizer, and Galapagos and has received unrestricted research grants from Takeda, Janssen, and Pfizer; all other authors declare that they have no conflict of interest.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
van de Pol, N., van der Woude, C.J., Vis, M. et al. Patients with immune mediated inflammatory diseases are insufficiently protected against vaccine-preventable infections. Infection (2024). https://doi.org/10.1007/s15010-024-02373-z
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s15010-024-02373-z